P.26 Adjuvant treatment for elderly patients with colon cancer in ten Italian medical oncology units

Pasetto, Lara Maria; Falci, Cristina; Basso, Umberto; Gasparini, G; D’Andrea, Marco Maria; Bonginelli, P.; Bajetta, Emilio; Platania, Marco; Alabisio, O.; Miraglia, Stefania; Bertona, E.; Oniga, Francesco; Biason, R.; Chetri, M.C.; Fedele, Palma; Massara, G; Romaniello, I.; Negru, Maria Emanuela; Giordano, M.; Luchena, Giovanna; Buzzi, Franco; Ricotta, Riccardo; Siena, Salvatore; Monfardini, S.

doi:10.1016/s1040-8428(13)70199-9

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though these guidelines suggest treatment options up to the third or even the fourth line of therapy, there are no predictive indicators that can discriminate, at the beginning of the sequence, which patients will actually receive further treatment after the failure of first-line. Indeed, the literature about the probability of a patient submitted to a first line to receive further lines of therapy is scanty, with only anecdotal papers describing the proportion of patients submitted to each line of therapy [15][16][17] . These studies, however, considered data from particular subsets of patients (elderly patients and patients living in rural zones).…”

Section: Discussionmentioning

confidence: 99%

Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit

Tampellini

Maïo

Baratelli

et al. 2017

Clinical Colorectal Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit

Tampellini

Maïo

Baratelli

et al. 2017

Clinical Colorectal Cancer

View full text Add to dashboard Cite

show abstract

“…CRC is a common type of malignant tumour with a high rate of morbidity and mortality (Pasetto et al, 2008). Liposomes, as carriers of chemotherapeutic agents, can change the distribution of these agents within the body and decrease drug toxicity.…”

Section: Discussionmentioning

confidence: 99%

PEG‐liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase‐8

Yang

Liu

2012

Cell Biology International

View full text Add to dashboard Cite

Since cellular uptake of PEG [poly(ethylene glycol)]-liposomal L-OHP (oxaliplatin) induces bioactive changes in CRC (colorectal cancer), we have investigated its apoptotic effect and anticancer mechanism. Human CRC SW480 cells were treated with PEG-liposomal L-OHP and a caspase-8 inhibitor [Z-IETD-FMK (benzyloxycarbonyl-Ile-Glu-Thr-dl-Asp-fluoromethylketone)]. Apoptosis was measured by FCM (flow cytometry) and TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling) assay. Expression of Fas/FasL and cytochrome c was detected using FCM and an immunofluorescence assay. Expression of caspase-8, Bid, caspase-9, caspase-7 and activated caspase-3 (P17) was examined by Western blot analyses. The results indicated that PEG-liposomal L-OHP (28 μg/ml L-OHP) induced marked apoptosis in SW480 cells compared with 28 μg/ml free L-OHP. The expression levels of Fas, FasL, cytochrome c, caspase-9, caspase-7 and activated caspase-3 proteins were up-regulated, with a corresponding increase in apoptosis; however, expression of caspase-8 and Bid were down-regulated as apoptosis increased. When cells were treated with Z-IETD-FMK, apoptosis was inhibited, but there was little impact on the expression of Fas, FasL, cytochrome c, Bid, caspase-9, caspase-7 and activated caspase-3. These findings indicate that PEG-liposomal L-OHP enhances the anticancer potency of the chemotherapeutic agent; moreover, Fas/FasL and caspase-8 signalling pathways play a key role in mediating PEG-liposomal L-OHP-induced apoptosis.

show abstract

“…This may be why patients with comorbidities are less likely to receive adjuvant chemotherapy. (31–34) In a study using SEER-Medicare database, older adults with resected stage III colorectal cancer with comorbidities were less likely to be referred to a medical oncologist for consideration of adjuvant chemotherapy and less likely to be given chemotherapy when seen by an oncologist. (33) The presence of comorbidities is one of the most frequent reasons for non-receipt of cancer treatment cited in the medical chart.…”

Section: Relevance In Cancermentioning

confidence: 99%

Comorbidity in older adults with cancer

Williams

MacKenzie

Magnuson

et al. 2016

Journal of Geriatric Oncology

239

169

View full text Add to dashboard Cite

Comorbidity is an issue of growing importance due to changing demographics and the increasing number of adults over the age of 65 with cancer. The best approach to the clinical management and decision-making in older adults with comorbid conditions remains unclear. In May 2015, the Cancer and Aging Research Group in collaboration with the National Cancer Institute and National Institute on Aging met to discuss the design and implementation of intervention studies in older adults with cancer. A presentation and discussion on comorbidity measurement, interventions, and future research was included. In this article we discuss the relevance of comorbidities in cancer, examine the commonly used tools to measure comorbidity, and discuss the future direction of comorbidity research. Incorporating standardized comorbidity measurement, relaxing clinical trial eligibility criteria, and utilizing novel trial designs are critical to developing a larger and more generalizable evidence base to guide the management of these patients. Creating or adapting comorbidity management strategies for use in older adults with cancer is necessary to define optimal care for this growing population.

show abstract

P.26 Adjuvant treatment for elderly patients with colon cancer in ten Italian medical oncology units

Cited by 6 publications

References 0 publications

Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit

Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit

PEG‐liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase‐8

Comorbidity in older adults with cancer

Contact Info

Product

Resources

About